Global epidemiology and genetics of hepatocellular carcinoma

MR Toh, EYT Wong, SH Wong, AWT Ng, LH Loo… - Gastroenterology, 2023 - Elsevier
Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide. Classically, HCC
develops in genetically susceptible individuals who are exposed to risk factors, especially in …

Imaging to predict prognosis in hepatocellular carcinoma: current and future perspectives

M Ronot, V Chernyak, A Burgoyne, J Chang, H Jiang… - Radiology, 2023 - pubs.rsna.org
The focus of hepatocellular carcinoma (HCC) research for many years has been on
noninvasive diagnosis. Standardized systematic algorithms composed of combinations of …

Endoplasmic reticulum stress and autophagy in the pathogenesis of non-alcoholic fatty liver disease (NAFLD): current evidence and perspectives

CM Flessa, I Kyrou, N Nasiri-Ansari, G Kaltsas… - Current obesity …, 2021 - Springer
Abstract Purpose of Review Non-alcoholic fatty liver disease (NAFLD) is one of the most
common causes of chronic liver disease with rising prevalence worldwide. Herein, we …

Cholesterol metabolism: a double-edged sword in hepatocellular carcinoma

F Zhou, X Sun - Frontiers in Cell and Developmental Biology, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) represents a leading cause of cancer-related deaths
globally. The rising incidence of metabolic syndrome and its hepatic manifestation …

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD …

R Suvarna, S Shetty, JM Pappachan - Scientific Reports, 2024 - nature.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important public
health problem owing to its high prevalence and associated morbidity and mortality …

The Novel GlycoPEGylated FGF21 analog pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy …

M Rosenstock, L Tseng, A Pierce, E Offman… - … of Pharmacology and …, 2023 - ASPET
Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth
factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and …

Effect of isoquercitrin on free fatty acid-induced lipid accumulation in HepG2 cells

SH Kim, C Yun, D Kwon, YH Lee, JH Kwak, YS Jung - Molecules, 2023 - mdpi.com
Liver metabolic disorders and oxidative stress are crucial factors in the development of
nonalcoholic fatty liver disease (NAFLD); however, treatment strategies to combat NAFLD …

Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice

Z Lu, L Liu, S Zhao, J Zhao, S Li, M Li - Scientific Reports, 2023 - nature.com
Apigenin (APN), a flavone found in several plant foods with various biological properties
such as anti-obesity, anti-inflammation and other abilities, alleviates atherosclerosis and non …

The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women

E Molina‐Molina, GE Furtado, JG Jones… - European Journal of …, 2022 - Wiley Online Library
Background The prevalence and severity of nonalcoholic fatty liver disease (NAFLD)
increase in women after menopause. This narrative review discusses the causes and …

Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease

G Assante, S Chandrasekaran, S Ng, A Tourna… - Genome medicine, 2022 - Springer
Background The incidence of non-alcoholic fatty liver disease (NAFLD)-associated
hepatocellular carcinoma (HCC) is increasing worldwide, but the steps in precancerous …